RegulatoryJun 16, 2026, 04:02 PM
Lunai Bioworks Regains Nasdaq Minimum Bid Price Compliance
AI Summary
Lunai Bioworks Inc. announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq confirmed this on June 11, 2026, acknowledging the company met the terms from previous Panel decisions. However, Lunai Bioworks will be under a mandatory one-year Panel monitor. During this period, any future non-compliance with the Bid Price Rule would lead to a delist determination without the usual cure or compliance periods, though the company would retain the right to request a new hearing.
Key Highlights
- Lunai Bioworks regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price of $1.00 per share.
- Nasdaq confirmed compliance on June 11, 2026, noting the company met prior Panel decision terms.
- The company will be subject to a mandatory one-year Panel monitor from the date of Nasdaq's letter.
- During the monitoring period, future non-compliance with the Bid Price Rule will not allow for a compliance plan or cure period.
- A future non-compliance would result in a delist determination, with an option to request a new hearing.
Price Impact
More from LNAI